Page 18 - Eceptor News Today

Patients with HER2-positive breast cancer that has started to spread to other parts of the body survive for longer if they are treated with a new drug called pyrotinib, according to results from the longest follow-up of the PHOEBE randomized clinical trial in China.

Breast cancer is the most common form of cancer among women, with more than 2 million new cases diagnosed each year. In cases where the tumour remains localised in the breast, survival rates are remarkably high, at around 90%.

A large-scale meta-analysis in Molecular Psychiatry reveals that lifetime cannabis use is associated with DNA methylation changes in peripheral blood, which could have implications for understanding the long-term health effects of cannabis consumption.

The role of interleukin (IL)-6 and IL-1α in sterile intraamniotic inflammation (SIAI), a condition associated with preterm birth (PTB).

In a recent study published in the journal eGastroenterology, researchers delved into the latest therapeutic strategies for managing inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The paper discusses emerging treatments ranging from immune-modulating drugs and biologics to novel approaches like microRNA upregulators and stem cell therapies, highlighting the need for precision medicine in IBD care.

UCLA scientists have developed a new method to engineer more powerful immune cells that can potentially be used for "off-the-shelf" cell therapy to treat challenging cancers.

New research at ACR Convergence 2023, the American College of Rheumatology's annual meeting, demonstrates that CAR-T cell therapy could lead to sustained suppression of autoantibodies in treatment-resistant lupus while maintaining a robust response to vaccines.

Pharmacogenomics-based studies in the research for personalized therapeutics for dementia

A drug candidate developed by researchers at the University of Tennessee Health Science Center for advanced metastatic castration-resistant prostate cancer is now in its first clinical trial.

Researchers discover the BA.2.86 Omicron lineage with higher transmission potential than current dominant strains, yet show that existing antivirals remain effective. Despite its higher infectivity, BA.2.86 exhibits lower pathogenicity in hamsters, indicating decreased replication capacity may lead to less severe infections.